Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Recruitment Status
SUSPENDED
(See Contacts and Locations)Verified April 2026 by National Cancer Institute (NCI)
Sponsor
National Cancer Institute (NCI)
Information Provided by (Responsible Party)
National Cancer Institute (NCI)
Clinicaltrials.gov Identifier
NCT06568172
Other Study ID Numbers:
NCI-2024-03425
First Submitted
August 21, 2024
First Posted
August 22, 2024
Last Update Posted
May 12, 2026
Last Verified
April 2026

ClinicalTrials.gov processed this data on May 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

PRIMARY OBJECTIVE:

I. To determine if neoadjuvant immunotherapy combined with response-adapted oncologic surgery improves site-reported event-free survival (EFS) compared to standard-of-care surgery in resectable stage III/IV cutaneous squamous cell carcinoma (CSCC).

SECONDARY OBJECTIVES:

I. To compare utilization of adjuvant radiation between arms. II. To compare disease-free survival (DFS) between arms. III. To compare overall survival (OS) between arms. IV. To compare adverse events (Common Terminology Criteria for Adverse Events \[CTCAE\] version \[v\]5.0) between arms.

V. To assess pathologic complete response in arm 2.

PATIENT-REPORTED OUTCOMES:

I. Compare changes in patient reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) at 1, 6, and 12 months after surgery between treatment arms. (Primary objective) II. To compare patient reported symptoms functioning, and quality of life, as measured by the Cutaneous Squamous Cell Carcinoma NeoAdjuvant, Adjuvant and Perioperative 32 question scale (CSCC NAAP-32), Patient Reported Outcomes Measurement Information System (PROMIS)-Short Form (SF)-Anxiety, PROMIS-SF-Fatigue, and EuroQol-5D (EQ-5D), between arms at 1, 6, and 12 months after surgery.

III. Develop a scoring algorithm and validate the CSCC-NAAP-32 for use in this patient population.

EXPLORATORY OBJECTIVES:

I. To compare disease-specific survival (DSS) between arms. II. To correlate pathologic response with DFS in arm 2. III. To assess overall response rate (ORR) in arm 2. IV. To compare patterns of failure between arms. V. To compare pathologic measurements of lymph node yield between arms. VI. To compare primary tumor specimen dimensions and volume between arms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients undergo surgery per standard of care within 6 weeks of randomization. Starting within 6-12 weeks of surgery, patients may undergo image-guided radiation therapy (IGRT) with intensity modulated radiation therapy (IMRT) for 5 fractions per week for 6 weeks as clinically indicated. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET)/CT prior to treatment, and CT and/or MRI during follow up. Patients may also undergo optional collection of tissue, whole blood, and plasma on study.

ARM 2: Patients receive cemiplimab intravenously (IV) over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo response-adaptive surgery 21 days after last dose of cemiplimab. Starting within 12 weeks of surgery, patients may undergo IGRT with IMRT for 5 fractions per week for 6 weeks as clinically indicated. Starting within 6 weeks of completion of surgery or radiation therapy (if indicated), patients without pathologic complete response (pCR) receive cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or PET/CT prior to treatment, and CT and/or MRI on study and during follow up. Patients may also undergo optional collection of tissue, whole blood, and plasma on study.

After completion of study treatment, patients are followed up at 1, 6, and 12 months post-surgery then every 3 months for 2 years, every 6 months in year 3, and then annually thereafter.

Condition or DiseaseIntervention/Treatment
Eyelid Squamous Cell CarcinomaRecurrent Eyelid Squamous Cell CarcinomaRecurrent Skin Acantholytic Squamous Cell CarcinomaRecurrent Skin Clear Cell Squamous Cell CarcinomaRecurrent Skin Lymphoepithelial CarcinomaRecurrent Skin Spindle Cell Squamous Cell CarcinomaRecurrent Skin Squamous Cell Carcinoma With Sarcomatoid DifferentiationResectable Eyelid Squamous Cell CarcinomaResectable Skin Acantholytic Squamous Cell CarcinomaResectable Skin Clear Cell Squamous Cell CarcinomaResectable Skin Lymphoepithelial CarcinomaResectable Skin Spindle Cell Squamous Cell CarcinomaResectable Skin Squamous Cell Carcinoma With Sarcomatoid DifferentiationSkin Acantholytic Squamous Cell CarcinomaSkin Clear Cell Squamous Cell CarcinomaSkin Lymphoepithelial CarcinomaSkin Spindle Cell Squamous Cell CarcinomaSkin Squamous Cell Carcinoma With Sarcomatoid DifferentiationStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Procedure: Biospecimen CollectionProcedure: Biospecimen Collection

Study Design

Study TypeInterventional
Actual Enrollment420 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingSingle
Primary PurposeTreatment
Official TitleRandomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (C-PRE)
Study Start DateFebruary 17, 2025
Actual Primary Completion Date5yrs 2mos from now
Actual Study Completion Date5yrs 2mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Arm 1 (surgery, radiation)
Patients undergo surgery per standard of care within 6 weeks of randomization. Starting within 6-12 weeks of surgery, patients may undergo IGRT with IMRT for 5 fractions per week for 6 weeks as clinically indicated. Patients also undergo CT, MRI, and/or PET/CT prior to treatment, and CT and/or MRI during follow up. Patients may also undergo optional collection of tissue, whole blood, and plasma on study.
Procedure: Biospecimen Collection
Undergo collection of blood and/or plasma
Arm 2 (cemiplimab, surgery, radiation)
Patients receive cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo response-adaptive surgery 21 days after last dose of cemiplimab. Starting within 12 weeks of surgery, patients may undergo IGRT with IMRT for 5 fractions per week for 6 weeks as clinically indicated. Starting within 6 weeks of completion of surgery or radiation therapy (if indicated), patients without pCR receive cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or PET/CT prior to treatment, and CT and/or MRI on study and during follow up. Patients may also undergo optional collection of tissue, whole blood, and plasma on study.
Procedure: Biospecimen Collection
Undergo collection of blood and/or plasma

Outcome Measures

Primary Outcome Measures
  1. Event-free survival (EFS)
    Defined as the time from randomization to any of the following events: progression of disease that precludes surgery, toxic effects related to treatment that preclude surgery, inability to resect all gross disease), disease recurrence (local, regional, or distant) after surgery (or after radiographic complete response), disease progression after radiographic partial response or stable disease without surgery (or biopsy, as applicable), or death due to any cause, whichever occurs first. EFS rates will be estimated using the Kaplan-Meier method, and the stratified log-rank test will be used to assess whether perioperative immunotherapy (neoadjuvant/adjuvant) with response-adapted oncologic surgery improves EFS as recorded by the site compared to standard-of-care surgery in resectable stage III/IV cutaneous squamous cell carcinoma (CSCC).
Secondary Outcome Measures
  1. Utilization of adjuvant radiation
    Rates of utilization of adjuvant radiation for each arm will be computed using a binomial distribution assumption. A 95% confidence interval (CI) for the rate difference between arms will be calculated using the stratified Newcombe (Wilson) method (Yan 2010).
  2. Disease-free survival (DFS)
    DFS will use the same analytic methods as EFS.
  3. Overall survival (OS)
    OS will use the same analytic methods as EFS.
  4. Incidence of adverse events
    Adverse events (AEs) will be graded using Common Terminology Criteria for Adverse Events version (v) 5.0. Counts and frequencies of all AEs by grade will be provided by each treatment arm. For the experimental arm, AEs will be summarized for each treatment phase (neoadjuvant, adjuvant, and post-treatment \[after adjuvant\]). Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. The proportion of patients with at least one grade 3 or higher AE, serious AEs, AEs leading to discontinuation or death will be reported for each treatment arm. These analyses will be descriptive.
  5. Pathologic complete response
    Site-reported pathologic response will be assessed using the following categories: pathological complete, major, and partial response, no pathological response (i.e., no complete, major, or partial response), and no pathological evaluation. Pathological responses at 1 and 2 years will be summarized using frequencies and percentages and tested using a chi-square test at a two-sided 5% significance level.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Pathologically (histologically or cytologically) proven diagnosis of invasive cutaneous squamous cell carcinoma (CSCC) or regional lymph node or in-transit metastasis of CSCC
The following CSCC subtypes are eligible according to World Health Organization (WHO) classification if the predominant histology is confirmed CSCC.
Spindle cell squamous cell carcinoma (SCC)
Squamous cell carcinoma with sarcomatoid differentiation
Acantholytic SCC
Clear cell SCC
Lymphoepithelial carcinoma
Note: Keratoacanthoma SCC and Verrucous SCC subtypes are not eligible.
For patients with regional metastasis without a primary tumor at screening: a clinical history of CSCC that drains to the involved regional lymph nodes or in-transit metastases in question is required
For example, a parotid mass shown to be SCC by cytologic analysis of a fine needle aspirate in a patient with a clinical history of CSCC on the ipsilateral scalp would be eligible
For patients with regional metastases without a primary tumor and an ambiguous clinical history: tumor genomic sequencing suggesting a primary tumor of cutaneous origin would be acceptable evidence to establish eligibility
NOTE: Tumor genomic sequencing is not required to determine eligibility, but may be part of the routine evaluation of patients with cancers of unknown primary at some institutions. For example, a parotid mass shown to be SCC by cytologic analysis of fine needle aspirate without a primary tumor and an ambiguous clinical history, but with a tumor genomic sequencing assay demonstrating a high tumor mutation burden (≥ 10 mutations/Mb) and/or a high fraction of ultraviolet (UV) related mutations (\> 50% of mutations \[cytosine (C)/thymine (T)\]C \> T or CC \> TT) and/or the presence of "signature 7" mutations would be eligible (Chang 2021)
Previously untreated or recurrent CSCC
Clinical American Joint Committee on Cancer (AJCC) 8th Edition (eyelid, head and neck sites) or Union for International Cancer Control (UICC) (non-head and neck sites) stage III or IV
Primary tumor site must be in the head and neck cutaneous region, other non-head and neck cutaneous regions, or eyelid cutaneous region
No mucosal squamous cell carcinoma (vermillion lip, nasal, oral, sinonasal, conjunctival, anogenital)
Tumor must be resectable with curative intent. Note: Tumor with bony skull base invasion and/or skull base foramen involvement (T4b) is not eligible. (Patients with T4b eyelid tumors using UICC Staging, and not involving the brain, are eligible.)
At least 1 lesion that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
No definitive clinical or radiologic evidence of distant metastatic disease (M1), visceral and/or distant nodal disease
Age ≥ 18
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Not pregnant and not nursing
Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
Absolute neutrophil count (ANC) ≥ 1,000 cells/mm\^3
Platelets ≥ 75,000 cells/mm\^3
Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 8.0 g/dl is acceptable)
Creatinine clearance (CrCL) \> 30mL/min by the Cockcroft-Gault formula
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (NOTE: For patients with Gilbert's syndrome, total bilirubin ≤ 3 x ULN. Gilbert's syndrome must be documented appropriately as past medical history.)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 x institutional ULN
No prior systemic therapy for the study cancer (including patients currently receiving immunotherapy for a separate malignancy)
No prior radiotherapy to the region of the study cancer that would result in cumulative doses of radiation to organs at risk for radiation injury that exceed protocol limitations
No history of myocardial infarction/unstable angina within the last 6 months
New York Heart Association functional classification IIb or better (New York Heart Association \[NYHA\] functional classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification)
No active infection requiring systemic antibiotics, antiviral, or antifungal treatments
No history of allogeneic stem cell transplantation, or autologous stem cell transplantation
No history of a solid organ transplant (other than corneal transplant)
No active, known, or suspected autoimmune disease
Active or known disease is defined as:
Requiring higher than physiologic steroid levels (\> 10mg prednisone/day or equivalent) or
Requiring disease-modifying agents or
Ongoing or recent (within 5 years prior to registration) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs)
NOTES:
Patients meeting the following criteria are not considered immunosuppressed and are eligible to enroll:
Patients who require a brief course of steroids (eg, prophylaxis for imaging assessments due to hypersensitivity to contrast agents) are not excluded
Patients with type I diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
Physiologic replacement doses ≤ 10 mg prednisone/day or equivalent allowed, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted
Patients with the following immunosuppressed conditions are eligible to enroll:
Patients with HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible
Patients with chronic lymphocytic leukemia (CLL) with no history of anti-CLL therapy within 6 months prior to registration are eligible
No history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia)
No active, noninfectious pneumonitis requiring immune-suppressive therapy
No active tuberculosis
No live vaccines within 28 days prior to registration
No history of allergic reaction to the study agent, compounds of similar chemical or biologic composition to the study agent (or any of its excipients)
Exclusion Criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of invasive cutaneous squamous cell carcinoma (CSCC) or regional lymph node or in-transit metastasis of CSCC
The following CSCC subtypes are eligible according to World Health Organization (WHO) classification if the predominant histology is confirmed CSCC.
Spindle cell squamous cell carcinoma (SCC)
Squamous cell carcinoma with sarcomatoid differentiation
Acantholytic SCC
Clear cell SCC
Lymphoepithelial carcinoma
Note: Keratoacanthoma SCC and Verrucous SCC subtypes are not eligible.
For patients with regional metastasis without a primary tumor at screening: a clinical history of CSCC that drains to the involved regional lymph nodes or in-transit metastases in question is required
For example, a parotid mass shown to be SCC by cytologic analysis of a fine needle aspirate in a patient with a clinical history of CSCC on the ipsilateral scalp would be eligible
For patients with regional metastases without a primary tumor and an ambiguous clinical history: tumor genomic sequencing suggesting a primary tumor of cutaneous origin would be acceptable evidence to establish eligibility
NOTE: Tumor genomic sequencing is not required to determine eligibility, but may be part of the routine evaluation of patients with cancers of unknown primary at some institutions. For example, a parotid mass shown to be SCC by cytologic analysis of fine needle aspirate without a primary tumor and an ambiguous clinical history, but with a tumor genomic sequencing assay demonstrating a high tumor mutation burden (≥ 10 mutations/Mb) and/or a high fraction of ultraviolet (UV) related mutations (\> 50% of mutations \[cytosine (C)/thymine (T)\]C \> T or CC \> TT) and/or the presence of "signature 7" mutations would be eligible (Chang 2021)
Previously untreated or recurrent CSCC
Clinical American Joint Committee on Cancer (AJCC) 8th Edition (eyelid, head and neck sites) or Union for International Cancer Control (UICC) (non-head and neck sites) stage III or IV
Primary tumor site must be in the head and neck cutaneous region, other non-head and neck cutaneous regions, or eyelid cutaneous region
No mucosal squamous cell carcinoma (vermillion lip, nasal, oral, sinonasal, conjunctival, anogenital)
Tumor must be resectable with curative intent. Note: Tumor with bony skull base invasion and/or skull base foramen involvement (T4b) is not eligible. (Patients with T4b eyelid tumors using UICC Staging, and not involving the brain, are eligible.)
At least 1 lesion that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
No definitive clinical or radiologic evidence of distant metastatic disease (M1), visceral and/or distant nodal disease
Age ≥ 18
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Not pregnant and not nursing
Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
Absolute neutrophil count (ANC) ≥ 1,000 cells/mm\^3
Platelets ≥ 75,000 cells/mm\^3
Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 8.0 g/dl is acceptable)
Creatinine clearance (CrCL) \> 30mL/min by the Cockcroft-Gault formula
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (NOTE: For patients with Gilbert's syndrome, total bilirubin ≤ 3 x ULN. Gilbert's syndrome must be documented appropriately as past medical history.)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 x institutional ULN
No prior systemic therapy for the study cancer (including patients currently receiving immunotherapy for a separate malignancy)
No prior radiotherapy to the region of the study cancer that would result in cumulative doses of radiation to organs at risk for radiation injury that exceed protocol limitations
No history of myocardial infarction/unstable angina within the last 6 months
New York Heart Association functional classification IIb or better (New York Heart Association \[NYHA\] functional classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification)
No active infection requiring systemic antibiotics, antiviral, or antifungal treatments
No history of allogeneic stem cell transplantation, or autologous stem cell transplantation
No history of a solid organ transplant (other than corneal transplant)
No active, known, or suspected autoimmune disease
Active or known disease is defined as:
Requiring higher than physiologic steroid levels (\> 10mg prednisone/day or equivalent) or
Requiring disease-modifying agents or
Ongoing or recent (within 5 years prior to registration) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs)
NOTES:
Patients meeting the following criteria are not considered immunosuppressed and are eligible to enroll:
Patients who require a brief course of steroids (eg, prophylaxis for imaging assessments due to hypersensitivity to contrast agents) are not excluded
Patients with type I diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
Physiologic replacement doses ≤ 10 mg prednisone/day or equivalent allowed, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted
Patients with the following immunosuppressed conditions are eligible to enroll:
Patients with HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible
Patients with chronic lymphocytic leukemia (CLL) with no history of anti-CLL therapy within 6 months prior to registration are eligible
No history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia)
No active, noninfectious pneumonitis requiring immune-suppressive therapy
No active tuberculosis
No live vaccines within 28 days prior to registration
No history of allergic reaction to the study agent, compounds of similar chemical or biologic composition to the study agent (or any of its excipients)

Contacts and Locations

Sponsors and CollaboratorsNational Cancer Institute (NCI)
Locations
University of Alabama at Birmingham Cancer Center | Birmingham Alabama, United States, 35233Banner MD Anderson Cancer Center | Gilbert Arizona, United States, 85234Mayo Clinic Hospital in Arizona | Phoenix Arizona, United States, 85054Tower Cancer Research Foundation | Beverly Hills California, United States, 90211City of Hope Comprehensive Cancer Center | Duarte California, United States, 91010UC San Diego Health System - Encinitas | Encinitas California, United States, 92024City of Hope at Irvine Lennar | Irvine California, United States, 92618UC San Diego Moores Cancer Center | La Jolla California, United States, 92093City of Hope Antelope Valley | Lancaster California, United States, 93534The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles California, United States, 90025USC / Norris Comprehensive Cancer Center | Los Angeles California, United States, 90033Cedars-Sinai Medical Center | Los Angeles California, United States, 90048Kaiser Permanente-Oakland | Oakland California, United States, 94611Stanford Cancer Institute Palo Alto | Palo Alto California, United States, 94304University of California Davis Comprehensive Cancer Center | Sacramento California, United States, 95817Kaiser Permanente-South Sacramento | Sacramento California, United States, 95823UC San Diego Medical Center - Hillcrest | San Diego California, United States, 92103Kaiser Permanente-San Francisco | San Francisco California, United States, 94115City of Hope South Pasadena | South Pasadena California, United States, 91030Torrance Memorial Physician Network - Cancer Care | Torrance California, United States, 90505City of Hope Upland | Upland California, United States, 91786Kaiser Permanente-Walnut Creek | Walnut Creek California, United States, 94596UCHealth University of Colorado Hospital | Aurora Colorado, United States, 80045UCHealth Memorial Hospital Central | Colorado Springs Colorado, United States, 80909Memorial Hospital North | Colorado Springs Colorado, United States, 80920Smilow Cancer Hospital Care Center at Greenwich | Greenwich Connecticut, United States, 06830Smilow Cancer Hospital Care Center - Guilford | Guilford Connecticut, United States, 06437Yale University | New Haven Connecticut, United States, 06520Smilow Cancer Hospital Care Center-Trumbull | Trumbull Connecticut, United States, 06611Smilow Cancer Hospital-Waterbury Care Center | Waterbury Connecticut, United States, 06708Smilow Cancer Hospital Care Center - Waterford | Waterford Connecticut, United States, 06385Helen F Graham Cancer Center | Newark Delaware, United States, 19713Medical Oncology Hematology Consultants PA | Newark Delaware, United States, 19713UM Sylvester Comprehensive Cancer Center at Aventura | Aventura Florida, United States, 33180UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables Florida, United States, 33146UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach Florida, United States, 33442UM Sylvester Comprehensive Cancer Center at Doral | Doral Florida, United States, 33166Mayo Clinic in Florida | Jacksonville Florida, United States, 32224-9980University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami Florida, United States, 33136Miami Cancer Institute | Miami Florida, United States, 33176UM Sylvester Comprehensive Cancer Center at Kendall | Miami Florida, United States, 33176Sarasota Memorial Hospital-Venice | N. Venice Florida, United States, 34275UM Sylvester Comprehensive Cancer Center at Plantation | Plantation Florida, United States, 33324Florida Cancer Specialists - Sarasota | Sarasota Florida, United States, 34232Florida Cancer Specialists - Sarasota Downtown | Sarasota Florida, United States, 34236First Physicians Group - Silverstein Institute at Floyd Street | Sarasota Florida, United States, 34239Sarasota Memorial Hospital | Sarasota Florida, United States, 34239Sarasota Memorial Health Care Center at University Parkway | Sarasota Florida, United States, 34243Moffitt Cancer Center-International Plaza | Tampa Florida, United States, 33607Moffitt Cancer Center - McKinley Campus | Tampa Florida, United States, 33612Moffitt Cancer Center | Tampa Florida, United States, 33612Florida Cancer Specialists - Venice Pinebrook | Venice Florida, United States, 34275Florida Cancer Specialists - Venice Island | Venice Florida, United States, 34285Emory University Hospital Midtown | Atlanta Georgia, United States, 30308Emory University Hospital/Winship Cancer Institute | Atlanta Georgia, United States, 30322Alton Memorial Hospital | Alton Illinois, United States, 62002Northwestern University | Chicago Illinois, United States, 60611Rush MD Anderson Cancer Center | Chicago Illinois, United States, 60612University of Illinois | Chicago Illinois, United States, 60612Decatur Memorial Hospital | Decatur Illinois, United States, 62526Northwestern Medicine Cancer Center Kishwaukee | DeKalb Illinois, United States, 60115Northwestern Medicine Cancer Center Delnor | Geneva Illinois, United States, 60134Northwestern Medicine Orland Park | Orland Park Illinois, United States, 60462Memorial Hospital East | Shiloh Illinois, United States, 62269Northwestern Medicine Cancer Center Warrenville | Warrenville Illinois, United States, 60555IU Health North Hospital | Carmel Indiana, United States, 46032Goshen Center for Cancer Care | Goshen Indiana, United States, 46526Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis Indiana, United States, 46202Franciscan Health Indianapolis | Indianapolis Indiana, United States, 46237Heartland Oncology and Hematology LLP | Council Bluffs Iowa, United States, 51503Methodist Jennie Edmundson Hospital | Council Bluffs Iowa, United States, 51503University of Kansas Cancer Center | Kansas City Kansas, United States, 66160University of Kansas Cancer Center-Overland Park | Overland Park Kansas, United States, 66210University of Kansas Hospital-Indian Creek Campus | Overland Park Kansas, United States, 66211University of Kansas Hospital-Westwood Cancer Center | Westwood Kansas, United States, 66205University of Kentucky/Markey Cancer Center | Lexington Kentucky, United States, 40536The James Graham Brown Cancer Center at University of Louisville | Louisville Kentucky, United States, 40202UofL Health Medical Center Northeast | Louisville Kentucky, United States, 40245LSU Health Baton Rouge-North Clinic | Baton Rouge Louisiana, United States, 70805Our Lady of the Lake Physician Group | Baton Rouge Louisiana, United States, 70808University Medical Center New Orleans | New Orleans Louisiana, United States, 70112University of Michigan Rogel Cancer Center | Ann Arbor Michigan, United States, 48109University of Michigan - Brighton Center for Specialty Care | Brighton Michigan, United States, 48116Henry Ford Hospital | Detroit Michigan, United States, 48202Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids Michigan, United States, 49503Henry Ford West Bloomfield Hospital | West Bloomfield Michigan, United States, 48322University of Michigan Health - West | Wyoming Michigan, United States, 49519University of Minnesota/Masonic Cancer Center | Minneapolis Minnesota, United States, 55455Mayo Clinic in Rochester | Rochester Minnesota, United States, 55905Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters Missouri, United States, 63376MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia Missouri, United States, 65212Siteman Cancer Center at West County Hospital | Creve Coeur Missouri, United States, 63141University of Kansas Cancer Center - North | Kansas City Missouri, United States, 64154University of Kansas Cancer Center - Lee's Summit | Lee's Summit Missouri, United States, 64064Washington University School of Medicine | St Louis Missouri, United States, 63110Siteman Cancer Center-South County | St Louis Missouri, United States, 63129Siteman Cancer Center at Christian Hospital | St Louis Missouri, United States, 63136Nebraska Medicine-Bellevue | Bellevue Nebraska, United States, 68123Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha Nebraska, United States, 68114Nebraska Methodist Hospital | Omaha Nebraska, United States, 68114Nebraska Medicine-Village Pointe | Omaha Nebraska, United States, 68118University of Nebraska Medical Center | Omaha Nebraska, United States, 68198Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon New Hampshire, United States, 03756Memorial Sloan Kettering Basking Ridge | Basking Ridge New Jersey, United States, 07920Memorial Sloan Kettering Monmouth | Middletown New Jersey, United States, 07748Memorial Sloan Kettering Bergen | Montvale New Jersey, United States, 07645University of New Mexico Cancer Center | Albuquerque New Mexico, United States, 87106Memorial Sloan Kettering Commack | Commack New York, United States, 11725Memorial Sloan Kettering Westchester | Harrison New York, United States, 10604Northwell Health/Center for Advanced Medicine | Lake Success New York, United States, 11042NYU Langone Hospital - Long Island | Mineola New York, United States, 11501Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York New York, United States, 10016Manhattan Eye Ear and Throat Hospital | New York New York, United States, 10065Memorial Sloan Kettering Cancer Center | New York New York, United States, 10065Lenox Hill Hospital | New York New York, United States, 10075University of Rochester | Rochester New York, United States, 14642Stony Brook University Medical Center | Stony Brook New York, United States, 11794State University of New York Upstate Medical University | Syracuse New York, United States, 13210SUNY Upstate Medical Center-Community Campus | Syracuse New York, United States, 13215Montefiore Medical Center-Einstein Campus | The Bronx New York, United States, 10461Montefiore Medical Center-Weiler Hospital | The Bronx New York, United States, 10461Montefiore Medical Center - Moses Campus | The Bronx New York, United States, 10467Memorial Sloan Kettering Nassau | Uniondale New York, United States, 11553Wilmot Cancer Institute at Webster | Webster New York, United States, 14580Atrium Health Stanly/LCI-Albemarle | Albemarle North Carolina, United States, 28002UNC Lineberger Comprehensive Cancer Center | Chapel Hill North Carolina, United States, 27599Carolinas Medical Center/Levine Cancer Institute | Charlotte North Carolina, United States, 28203Atrium Health Pineville/LCI-Pineville | Charlotte North Carolina, United States, 28210Atrium Health University City/LCI-University | Charlotte North Carolina, United States, 28262Atrium Health Cabarrus/LCI-Concord | Concord North Carolina, United States, 28025Duke University Medical Center | Durham North Carolina, United States, 27710Levine Cancer Institute-Gaston | Gastonia North Carolina, United States, 28054Atrium Health Union/LCI-Union | Monroe North Carolina, United States, 28112Duke Cancer Center Raleigh | Raleigh North Carolina, United States, 27609Atrium Health Cleveland/LCI-Cleveland | Shelby North Carolina, United States, 28150Wake Forest University Health Sciences | Winston-Salem North Carolina, United States, 27157UH Seidman Cancer Center at UH Avon Health Center | Avon Ohio, United States, 44011UHHS-Chagrin Highlands Medical Center | Beachwood Ohio, United States, 44122Miami Valley Hospital South | Centerville Ohio, United States, 45459University of Cincinnati Cancer Center-UC Medical Center | Cincinnati Ohio, United States, 45219Case Western Reserve University | Cleveland Ohio, United States, 44106MetroHealth Medical Center | Cleveland Ohio, United States, 44109Ohio State University Comprehensive Cancer Center | Columbus Ohio, United States, 43210Miami Valley Hospital North | Dayton Ohio, United States, 45415Atrium Medical Center-Middletown Regional Hospital | Franklin Ohio, United States, 45005-1066Miami Valley Cancer Care and Infusion | Greenville Ohio, United States, 45331UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor Ohio, United States, 44060Upper Valley Medical Center | Troy Ohio, United States, 45373University of Cincinnati Cancer Center-West Chester | West Chester Ohio, United States, 45069University of Oklahoma Health Sciences Center | Oklahoma City Oklahoma, United States, 73104Providence Portland Medical Center | Portland Oregon, United States, 97213Christiana Care Health System-Concord Health Center | Chadds Ford Pennsylvania, United States, 19317UPMC Hillman Cancer Center Erie | Erie Pennsylvania, United States, 16505Saint Vincent Hospital | Erie Pennsylvania, United States, 16544Penn State Milton S Hershey Medical Center | Hershey Pennsylvania, United States, 17033-0850UPMC-Johnstown/John P. Murtha Regional Cancer Center | Johnstown Pennsylvania, United States, 15901Forbes Hospital | Monroeville Pennsylvania, United States, 15146Thomas Jefferson University Hospital | Philadelphia Pennsylvania, United States, 19107Fox Chase Cancer Center | Philadelphia Pennsylvania, United States, 19111Allegheny General Hospital | Pittsburgh Pennsylvania, United States, 15212West Penn Hospital | Pittsburgh Pennsylvania, United States, 15224University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh Pennsylvania, United States, 15232Wexford Health and Wellness Pavilion | Wexford Pennsylvania, United States, 15090Medical University of South Carolina | Charleston South Carolina, United States, 29425Rock Hill Radiation Therapy Center | Rock Hill South Carolina, United States, 29730Levine Cancer Institute-Rock Hill | Rock Hill South Carolina, United States, 29732Vanderbilt University/Ingram Cancer Center | Nashville Tennessee, United States, 37232MD Anderson in The Woodlands | Conroe Texas, United States, 77384UT Southwestern Simmons Cancer Center - RedBird | Dallas Texas, United States, 75237UT Southwestern/Simmons Cancer Center-Dallas | Dallas Texas, United States, 75390UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth Texas, United States, 76104M D Anderson Cancer Center | Houston Texas, United States, 77030MD Anderson West Houston | Houston Texas, United States, 77079MD Anderson League City | League City Texas, United States, 77573UT Southwestern Clinical Center at Richardson/Plano | Richardson Texas, United States, 75080University of Texas Health Science Center at San Antonio | San Antonio Texas, United States, 78229MD Anderson in Sugar Land | Sugar Land Texas, United States, 77478Huntsman Cancer Institute/University of Utah | Salt Lake City Utah, United States, 84112Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners Vermont, United States, 05602University of Vermont Medical Center | Burlington Vermont, United States, 05401University of Vermont and State Agricultural College | Burlington Vermont, United States, 05405Dartmouth Cancer Center - North | Saint Johnsbury Vermont, United States, 05819University of Virginia Cancer Center | Charlottesville Virginia, United States, 22908Inova Schar Cancer Institute | Fairfax Virginia, United States, 22031VCU Massey Comprehensive Cancer Center | Richmond Virginia, United States, 23298Virginia Mason Medical Center | Seattle Washington, United States, 98101Gundersen Lutheran Medical Center | La Crosse Wisconsin, United States, 54601William S Middleton VA Medical Center | Madison Wisconsin, United States, 53705University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison Wisconsin, United States, 53718University of Wisconsin Carbone Cancer Center - University Hospital | Madison Wisconsin, United States, 53792Marshfield Medical Center-Marshfield | Marshfield Wisconsin, United States, 54449Froedtert Menomonee Falls Hospital | Menomonee Falls Wisconsin, United States, 53051Medical College of Wisconsin | Milwaukee Wisconsin, United States, 53226Drexel Town Square Health Center | Oak Creek Wisconsin, United States, 53154Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend Wisconsin, United States, 53095Marshfield Medical Center - Weston | Weston Wisconsin, United States, 54476Chris O'Brien Lifehouse | Camperdown New South Wales, Australia, 2050Wollongong Hospital | Wollongong New South Wales, Australia, 2500Townsville General Hospital | Townsville Queensland, Australia, 4814Princess Alexandra Hospital | Woolloongabba Queensland, Australia, 4102Saint Vincent's Hospital | Fitzroy Victoria, Australia, 3065Peter MacCallum Cancer Centre | Melbourne Victoria, Australia, 3000Fiona Stanley Hospital | Murdoch Western Australia, Australia, 6150BCCA-Vancouver Cancer Centre | Vancouver British Columbia, Canada, V5Z 4E6Odette Cancer Centre- Sunnybrook Health Sciences Centre | Toronto Ontario, Canada, M4N 3M5University Health Network-Princess Margaret Hospital | Toronto Ontario, Canada, M5G 2M9
Investigators
Principal Investigator: Neil D Gross, NRG Oncology